참고문헌
- Alibhai SM, Naglie G, Nam R, et al (2003). Do older men benefit from curative therapy of localized prostate cancer? J Clin Oncol, 21, 3318-27 https://doi.org/10.1200/JCO.2003.09.034
- Andiole GL, Grubb RL III, Buys SS, et al (2009). Mortality results from a randomized prostate cancer screening trial. NEJM, 360, 1310-19. https://doi.org/10.1056/NEJMoa0810696
- Anastasiadis E, van der Meulen J, Emberton M (2014). Hospital admissions after TRUS biopsy of the prostate in men diagnoses with prostate cancer: A database analysis in England. Int J Urol, (in Press).
- Beach R, Gown AM, Peralta-Venturina MN et al (2002). P504S immunohistochemical detection in 405 prostatic specimens including 376 18-guage needle biopsies. Am J Surg Pathol, 26, 1588-96. https://doi.org/10.1097/00000478-200212000-00006
- Becker D, Ryemon S, Gross J, et al (2014). Cancer trends among the extreme elderly in the era of cancer screening. J Geriatr Oncol, 1, 408-14.
- Belbase NP, Agrawal CS, Pokharel PK, et al (2013). Prostate cancer screening in a healthy population cohort in Eastern Nepal: an explanatory trial study. Asian Pac J Cancer Prev, 14, 2835-8. https://doi.org/10.7314/APJCP.2013.14.5.2835
- Borgen E, Naume B, Nesland JM, et al (1999). Standardization of the immunocytochemical detection of cancer cells in BM and blood. I. Establishment of objective criteria for the evaluation of immunostained cells, Cytotherapy, 1, 377-388. https://doi.org/10.1080/0032472031000141283
- Bozeman CB, Carver BS, Eastham JA, et al (2002). Treatment of chronic prostatitis lowers serum prostate specific antigen, J Urol, 167, 1723-6. https://doi.org/10.1016/S0022-5347(05)65186-5
- Campbell MF, Wein AJ, Kavoussi LR (2011). Campbell's Urology. V, Section II, chapter, 3, 2011.
- Carter HB, Albertsen PC, Barry MJ, et al (2013). Early detection of prostate cancer: AUA guideline. J Urol, 190, 419-26 https://doi.org/10.1016/j.juro.2013.04.119
- Delongchamps NB, Wang CY, Chandan V, et al (2009). Pathological characteristics of prostate cancer in elderly men. J Urol, 182, 927-30 https://doi.org/10.1016/j.juro.2009.05.018
- Droz JP, Aapro M, Balducci L et al (2014). Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol, 15, e404-414. https://doi.org/10.1016/S1470-2045(14)70018-X
- Epstein JI, Walsh PC, Carmichael M (1994). Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer, JAMA, 271, 368-74. https://doi.org/10.1001/jama.1994.03510290050036
- Fehm T, Solomayer EF, Meng S et al (2005). Methods for isolating circulating epithelial cells and criteria for their classification as carcinoma cells, Cytotherapy, 7, 171-85. https://doi.org/10.1080/14653240510027082
- Ferlay J, Autier P, Bonial M et al (2007). Estimates of cancer incidence and mortality in Europe in 2006. Ann Oncol, 18, 581-92
- Gandaglia G, Karakiewicz PI, Abdollah F, et al (2014). The effect of age at diagnosis on prostate cancer mortality: A grade for grade and stage for stage analysis. Eur J Surg Oncol, 40, 1706-1715 https://doi.org/10.1016/j.ejso.2014.05.001
- Gann PH, Hennekens CH, Stampfer MJ (1995). A prospective evaluation of plasma PSA for detection of prostate cancer. JAMA, 273, 289-94. https://doi.org/10.1001/jama.1995.03520280035036
- Heidenrich A, Bastian PJ, Bellmunt J, et al (2012). Guidelines on prostate cancer. Arnhem, Netherlands. European Association of Urology www.eau.org
- Jemal A, Siegel R, Ward E et al (2008). Cancer statistics 2008. CA Cancer J Clin, 58, 71-96 https://doi.org/10.3322/CA.2007.0010
- Lalitha K, Suman G, Pruthvish S, et al (2012). Estimation of time trends of incidence of prostate cancer: an Indian scenario. Asian Pac J Cancer Prev, 13, 6245-50 https://doi.org/10.7314/APJCP.2012.13.12.6245
- Mitsuzuka K, Koie T, Narita S, et al (2014). Late pathological and oncological outcomes of elderly men treated with radical prostatectomy worse than those of younger men? Matched pair analysis between patients aged <70 and >70 years. Jpn J Clin Oncol, 44, 587-92. https://doi.org/10.1093/jjco/hyu038
- Moreno JG, Croce CM, Fischer R, et al (1992). Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res, 52, 6110-2
- Murray NP, Reyes E, Badinez L, et al (2013), Circulating prostate cells found in men with benign prostate disease are P504S negative: clinical implications, J Oncology, 2013:165014.
- Murray NP, Reyes E, Fuentealba C et al. (2014). Extended use of P504S positive primary circulating prostate cell detection to determine the need for initial prostate biopsy in a prostate cancer screening program in Chile. Asian Pac J Cancer Prev, 15, 9335-9. https://doi.org/10.7314/APJCP.2014.15.21.9335
- Murray NP, Reyes E, Fuentealba C, et al (2014). Primary circulating prostate cells are not detected in low grade small volume prostate cancer. J Oncol, 2014, 612674.
- NCCN clinical practical guidelines in oncology: prostate cancer 2014. Available at http://www.nccn.org
- Panteleakou Z, Lembessis P, Sourla A et al. (2009), Detection of circulating tumor cells in prostate cancer patients:Methodological pitfalls and clinical relevance, Molecular Medicine, 15, 101-14.
- Paterlini-Brechot P, Benali NL (2007). Circulating tumor cells (CTC) detection: Clinical impact and future directions, Cancer Letters, 253, 180-204. https://doi.org/10.1016/j.canlet.2006.12.014
- Pavlakis K, Stravodimos K, Kapetanakis T et al (2010). Evaluation of routine application of P504S, 34bE12 and p63 immunostaining on 250 prostate needle biopsy specimens, Internat Urol Nephrol, 42, 325-30. https://doi.org/10.1007/s11255-009-9622-1
- Punglia RS, D'Amico AV, Catalona WJ et al (2006). Impact of age, benign prostatic hyperplasia, and cancer on prostatespecific antigen level, Cancer, 106, 1507-13. https://doi.org/10.1002/cncr.21766
- Ries LAG, Melbert D, Krapcho M et al (2009). SEER Cancer Statistics Review. 1975-2005 Betheseda MD: National Cancer Institute, 2008. Available at: http://seer.cancer.gov/csr/1975-2005, based on December 2009 SEER data submission.
- Rubin MA, Zhou M, Dhanasekaran SM et al (2002). a-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer, JAMA, 287, 1662-70. https://doi.org/10.1001/jama.287.13.1662
- Schroder FH, Hugosson J, Roobol MJ, et al (2009). Screening and prostate cancer mortality in a randomized European Study. NEJM, 360, 1320-8. https://doi.org/10.1056/NEJMoa0810084
- Situmorang GR, Umbas R, Mochtar CA et al (2012). Prostate cancer in younger and older patients: do we treat them differently? Asian Pac J Cancer Prev, 13, 4577-80 https://doi.org/10.7314/APJCP.2012.13.9.4577
- Sun L, Caire AA, Robertson CN, et al (2009). Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late PSA eras. J Urol, 182, 2242-9 https://doi.org/10.1016/j.juro.2009.07.034
- Verim L, Yildirim A, Basok ER, et al (2013). Impact of PSA and DRE on histologica findings at prostate biopsy in Turkish men over 75 years of age. Asian Pac J Cancer Prev, 14, 6085-8. https://doi.org/10.7314/APJCP.2013.14.10.6085
- Walter LC, Covinsky KE (2001). Cancer screening in elderly patients: a framework for individual decision making. JAMA, 285, 2750-6 https://doi.org/10.1001/jama.285.21.2750
- Went PT, Lugli A, Meier S, et al (2004). Frequent EpCam protein expression in human carcinomas. Human Pathology, 35, 122-8. https://doi.org/10.1016/j.humpath.2003.08.026
- Zhou M, Chinnaiyan AM, Lleer CG, et al (2002). Alphamethylacyl- CoA racemase: a novel tumor marker overexpressed in several human cancers and their precursor lesions. Am J Surg Pathol, 26, 926-31. https://doi.org/10.1097/00000478-200207000-00012
피인용 문헌
- Comparison of the Formula of PSA, Age, Prostate Volume and Race Versus PSA Density and the Detection of Primary Malignant Circulating Prostate Cells in Predicting a Positive Initial Prostate Biopsy in Chilean Men with Suspicion of Prostate Cancer vol.16, pp.13, 2015, https://doi.org/10.7314/APJCP.2015.16.13.5365